GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » E10

AVANIR Pharmaceuticals (FRA:AV2B) E10 : €-0.31 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AVANIR Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2014 was €-0.064. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.31 for the trailing ten years ended in Sep. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-20), AVANIR Pharmaceuticals's current stock price is €14.37. AVANIR Pharmaceuticals's E10 for the quarter that ended in Sep. 2014 was €-0.31. AVANIR Pharmaceuticals's Shiller PE Ratio of today is .


AVANIR Pharmaceuticals E10 Historical Data

The historical data trend for AVANIR Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals E10 Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.68 -0.58 -0.34 -0.31 -0.31

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.30 -0.30 -0.31 -0.31

Competitive Comparison of AVANIR Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Shiller PE Ratio falls into.



AVANIR Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AVANIR Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2014 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-0.064/100.4278*100.4278
=-0.064

Current CPI (Sep. 2014) = 100.4278.

AVANIR Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
200412 -0.224 80.290 -0.280
200503 -0.432 81.555 -0.532
200506 -0.255 82.062 -0.312
200509 -0.038 83.876 -0.045
200512 -0.270 83.032 -0.327
200603 -0.366 84.298 -0.436
200606 -0.442 85.606 -0.519
200609 -0.553 85.606 -0.649
200612 -0.295 85.142 -0.348
200703 -0.196 86.640 -0.227
200706 -0.171 87.906 -0.195
200709 0.135 87.964 0.154
200712 -0.089 88.616 -0.101
200803 -0.077 90.090 -0.086
200806 -0.013 92.320 -0.014
200809 -0.047 92.307 -0.051
200812 -0.052 88.697 -0.059
200903 -0.046 89.744 -0.051
200906 -0.043 91.003 -0.047
200909 -0.059 91.120 -0.065
200912 -0.041 91.111 -0.045
201003 -0.059 91.821 -0.065
201006 -0.049 91.962 -0.054
201009 -0.079 92.162 -0.086
201012 -0.083 92.474 -0.090
201103 -0.086 94.283 -0.092
201106 -0.090 95.235 -0.095
201109 -0.105 95.727 -0.110
201112 -0.091 95.213 -0.096
201203 -0.098 96.783 -0.102
201206 -0.088 96.819 -0.091
201209 -0.067 97.633 -0.069
201212 -0.069 96.871 -0.072
201303 -0.093 98.209 -0.095
201306 -0.061 98.518 -0.062
201309 -0.180 98.790 -0.183
201312 -0.051 98.326 -0.052
201403 -0.058 99.695 -0.058
201406 -0.059 100.560 -0.059
201409 -0.064 100.428 -0.064

Add all the adjusted EPS together and divide 10 will get our e10.


AVANIR Pharmaceuticals  (FRA:AV2B) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AVANIR Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines